title: [Surveillance of nalidixic acid-resistant and extended-spectrum beta-lactamase-producing Salmonella spp. isolated from human feces].
abstract: Nalidixic acid (NA)-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella sp. isolates from human specimens are associated with clinical failure or delayed response in subjects treated with fluoroquinolone or third-generation cephalosporins. We studied drug susceptibility in 604 Salmonella enterica isolates from human feces in 2007. Of these, 39 (6.5%) were resistat to NA. Of these, 46% were resistant to two or more drugs and 2% susceptible to NA were resistant to multiple drugs (p < 0.001). Three ESBL-producing Salmonella sp. isolated were of the CTX-M family gene type. One strain of plasmid-mediated AmpC beta-lactamase belonged to the CMY-2 family gene type. Our results thus showed that NA-resistant isolates were resistant to antimicrobial agents and confirmed the presence of a small number of isolates producing ESBL and AmpC beta-lactamase.
authors.affiliation: Central Laboratory Technical section 3, FALCO Biosystems Ltd.
authors.forename: Takuji
authors.initials: T
authors.lastname: Fujita
authors.forename: Masaru
authors.initials: M
authors.lastname: Komatsu
authors.forename: Junpei
authors.initials: J
authors.lastname: Okada
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Katoh
mesh_terms: D003428:Cross Infection / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D009268:Nalidixic Acid / Q000494:pharmacology*; D012475:Salmonella / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D001618:beta-Lactamases / Q000096:biosynthesis*
chemical_list: D009268:Nalidixic Acid; D001618:beta-Lactamases